A portable desktop shockwave unit, indicated across the same eleven conditions as MoreNova PRO, each with its own IFU-defined patient population.
MoreNova also publishes alopecia areata as a therapeutic area, though it sits outside the eleven indications listed in the IFU's section 8.2; DNA Nexus attributes that claim to the manufacturer only.
Erectile dysfunction: Males above 18. Vasculogenic ED, not psychological. Duration 6 months to 7 years. IIEF-6 score 11-25. Prescribed by a physician.Peyronie's disease: MaleChronic pelvic pain syndrome / LUTS: Males aged 18-70. Symptoms 3 months or more. CPPS Category IIIA/IIIB confirmed by a urologist. NIH-CPSI score above 15.Female sexual dysfunction: Females aged 20-70. Diagnosed FSAD or HSDD. Symptoms 6 months or more.Stress urinary incontinence: Females aged 20-75. Diagnosed by physical exam and urodynamic testing. Symptoms 3 months or more.Vulvodynia: Females aged 18-70Vaginal atrophy / genitourinary syndrome of menopause: Females aged 40-75, postmenopausalWound healing: AdultsPeripheral arterial disease: AdultsCellulite: AdultsMusculoskeletal disorders: AdultsMoreNova DT delivers the same indication set as the floor-standing MoreNova PRO, in a desktop unit.
From erectile dysfunction to wound healing, each with its own population criteria defined in section 8.2.
Same eleven indications. DT is a portable desktop unit; PRO is a floor-standing platform.
Yes. Population per IFU section 8.2.1: "Males above 18. Vasculogenic ED, not psychological. Duration 6 months to 7 years. IIEF-6 score 11-25. Prescribed by a physician."
Yes, in adults, per MoreNova's IFU.
Single-use transducer covers and ultrasound coupling gel, to the manufacturer's stated specification.
DNA Nexus will handle installation and set up MoreNova DT on site. After-sales technical support runs from Cairo, alongside the rest of the DNA Nexus shockwave portfolio.
MoreNova DT
